Protocol Ledger

NCT06057571 · Phase II · ACTIVE NOT RECRUITING

Study of TT-00420 (Tinengotinib) in Subjects With Cholangiocarcinoma Who Failed or Relapsed to Chemotherapy and FGFR Inhibitor

Interventional Phase II clinical trial protocol NCT06057571 sponsored by TransThera Sciences (Nanjing) in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-11-17 Enrollment: 50 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06057571
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)50 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06057571
Protocol FieldVerified Registry Value
NCT IdentifierNCT06057571
Consolidated Lead SponsorTransThera Sciences (Nanjing)
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment50 participants (ESTIMATED)
Registered Start Date2023-11-17
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI